CSI Market
Sign In | Register

Cumberland Pharmaceuticals Inc (CPIX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CPIX Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Cumberland Pharmaceuticals Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-7.56
Depreciation & amortization0.07
Amortization of Other Assets0.01
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.18
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Stock Based Compensation Nonemployees-
Stock Based Compensation Employees-
Increase Decrease In Prepaid Other Current Assets And Other Assets-
Sharebased Compensation Foundation Contribution-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Write Off Of Deferred Debt Issuance Cost-
Increase Decrease In Cash Surrender Value Of Life Insurance Policy-
Noncash Or Part Noncash Gain On Transaction-
Operating Lease Right Of Use Asset Amortization Expense0.29
Increase Decrease In Life Insurance Policies Over Premiums Paid0.09
Increase Decrease In Operating Lease Liability-0.23
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable-3.53
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.11
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital0.40
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities6.81
Discontinued operations4.05
Net Cash flow from Operating Activities0.56
Investing Activities
Capital Expenditures-0.05
Sale of Capital Items0.00
Proceeds from Sale of Short-term Investments0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Increase Decrease In Proceeds From Life Insurance Policy-
Proceeds From Settlement Of Patent Litigation-
Proceeds From Collaborative Arrangement-
Payments For Proceeds From Other Productive Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments to Acquire Life Insurance Policies-0.04
Other Net-1.75
Discontinued operations-0.15
Net Cash Flow from Investing Activities-1.99
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-5.24
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-0.06
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.85
Other net0.00
Payments for Contingent Consideration-
Proceeds From A T M Offering Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-6.15
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow0.51
Total Cash Flow-7.58
4 historic quarters locked

Sign in to unlock the full Cumberland Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Cumberland Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001087294-26-000062

Figures are derived from filed reports and may be restated. Historical data is subject to revision.